0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology

Buy Now

Resistance to Aromatase Inhibitors in Breast Cancer (Hardcover, 2015 ed.) Loot Price: R3,992
Discovery Miles 39 920
Resistance to Aromatase Inhibitors in Breast Cancer (Hardcover, 2015 ed.): Alexey Larionov

Resistance to Aromatase Inhibitors in Breast Cancer (Hardcover, 2015 ed.)

Alexey Larionov

Series: Resistance to Targeted Anti-Cancer Therapeutics, 8

 (sign in to rate)
Loot Price R3,992 Discovery Miles 39 920 | Repayment Terms: R374 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Aromatase Inhibitors (AIs) treat postmenopausal estrogen receptor positive tumours, which constitute the majority of breast cancer patients. This comprehensive volume brings together the current knowledge from different relevant areas, including molecular mechanisms and translational aspects of drug resistance in AIs. Topics covered include research, experimental , and clinical data specifically focused on AI resistance in breast cancer. The volume will include three sections. The first section covers general knowledge about aromatase inhibitors, including regulation of aromatase genes, and structure and function of aromatase protein. The second section provides the detailed mechanisms of resistance to AIs, while the third section explores prediction of resistance and potential strategies to overcome resistance. Breast cancer is the most common female cancer and AIs significantly improve treatments outcomes compatibly to previously used endocrine treatments. However 10-15% of post-operative patients develop a relapse during adjuvant treatment with AIs; about 25-50% of the patients do not respond to AIs in neo-adjuvant or metastatic setting, and the majority of metastatic patients who initially respond develop resistance within 3 years. There is an important need to understand these mechanisms of resistance in order to develop methods of preventing or overcoming the resistance to AIs, which will ensure a more successful outcome in treating breast cancer.

General

Imprint: Springer International Publishing AG
Country of origin: Switzerland
Series: Resistance to Targeted Anti-Cancer Therapeutics, 8
Release date: May 2015
First published: 2015
Editors: Alexey Larionov
Dimensions: 235 x 155 x 19mm (L x W x T)
Format: Hardcover
Pages: 288
Edition: 2015 ed.
ISBN-13: 978-3-319-17971-1
Categories: Books > Medicine > General issues > Medical equipment & techniques > Medical research
Books > Medicine > Pre-clinical medicine: basic sciences > Anatomy > General
Books > Medicine > Other branches of medicine > Pharmacology > General
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
LSN: 3-319-17971-3
Barcode: 9783319179711

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners